Exosome blood test could spot ovarian cancer return when standard tests fail
NCT ID NCT07153705
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study tests a new blood test called OCS that uses exosome technology to monitor for ovarian cancer recurrence. It focuses on patients whose CA125 levels were normal before initial treatment, making standard monitoring difficult. The trial will enroll 32 women with stage I-IV ovarian cancer who have completed surgery and chemotherapy.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
OCS exosome detection test
What this could lead to
If successful, this could provide a reliable way to detect ovarian cancer recurrence early in patients whose standard CA125 test is not informative.
What could go wrong
This is a small, early-stage study with only 32 participants, so results may not apply broadly. The test is experimental and not yet proven to be better than current methods.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.